- Home
- NCTY vs KZIA Comparison
NCTY vs KZIA Comparison
Compare NCTY & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | KZIA |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.8M | 93.2M |
| IPO Year | 2004 | 2002 |
Fundamental Metrics
Financial Performance| Metric | NCTY | KZIA |
|---|---|---|
| Price | $5.44 | $7.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 22.8K | ★ 129.5K |
| Earning Date | 03-27-2015 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $0.64 |
| 52 Week High | $15.98 | $17.40 |
Technical Indicators
Market Signals| Indicator | NCTY | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 46.86 |
| Support Level | $5.02 | $5.64 |
| Resistance Level | $7.22 | $8.05 |
| Average True Range (ATR) | 0.55 | 0.80 |
| MACD | -0.04 | -0.14 |
| Stochastic Oscillator | 15.93 | 18.12 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.